Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
- Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
- $4.2M Options Underwriting Agreement Executed
- Appendix 4E and 2026 Annual Report
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics